Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease.
Bose
Anindita
A
Inserm UMRS, Institut du Fer à Moulin, Paris, FranceDepartments of Histology Pathology The Memory Clinical Center, Lariboisière Hospital (APHP), University Paris Diderot VII, Paris, France.
Mouton-Liger
François
F
Paquet
Claire
C
Mazot
Pierre
P
Vigny
Marc
M
Gray
Françoise
F
Hugon
Jacques
J
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D015153:Blotting, Western; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002460:Cell Line; D004789:Enzyme Activation / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D007150:Immunohistochemistry; D018613:Microscopy, Confocal; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D010766:Phosphorylation; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D019892:eIF-2 Kinase / Q000378:metabolism*; D016875:tau Proteins / Q000187:drug effects / Q000378:metabolism*
D004791:Enzyme Inhibitors; D016875:tau Proteins; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D019892:eIF-2 Kinase; D038362:Glycogen Synthase Kinase 3